A systematic review of health economic models and utility estimation methods in schizophrenia

Bertalan Németh, Ahmad Fasseeh, Anett Molnár, I. Bitter, Margit Horváth, Kristóf Kóczián, Árpád Götze, Balázs Nagy

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Introduction: There is a growing need for economic evaluations describing the disease course, as well as the costs and clinical outcomes related to the treatment of schizophrenia. Areas covered: A systematic review on studies describing health economic models in schizophrenia and a targeted literature review on utility mapping algorithms in schizophrenia were carried out. Models found in the review were collated and assessed in detail according to their type and various other attributes. Fifty-nine studies were included in the review. Modeling techniques varied from simple decision trees to complex simulation models. The models used various clinical endpoints as value drivers, 47% of the models used quality-adjusted life years, and eight percent used disability-adjusted life years to measure benefits, while others applied various clinical outcomes. Most models considered patients switching between therapies, and therapeutic adherence, compliance or persistence. The targeted literature review identified four main approaches to map PANSS scores to utility values. Expert commentary: Health economic models developed for schizophrenia showed great variability, with simulation models becoming more frequently used in the last decade. Using PANSS scores as the basis of utility estimations is justifiable.

Original languageEnglish
Pages (from-to)267-275
Number of pages9
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume18
Issue number3
DOIs
Publication statusPublished - May 4 2018

Fingerprint

Economic Models
Schizophrenia
Quality-Adjusted Life Years
Health
Decision Trees
Compliance
Cost-Benefit Analysis
Therapeutics
Costs and Cost Analysis

Keywords

  • health economic models
  • Health economics
  • psychiatry
  • schizophrenia
  • systematic reviews

ASJC Scopus subject areas

  • Health Policy
  • Pharmacology (medical)

Cite this

A systematic review of health economic models and utility estimation methods in schizophrenia. / Németh, Bertalan; Fasseeh, Ahmad; Molnár, Anett; Bitter, I.; Horváth, Margit; Kóczián, Kristóf; Götze, Árpád; Nagy, Balázs.

In: Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 18, No. 3, 04.05.2018, p. 267-275.

Research output: Contribution to journalReview article

Németh, Bertalan ; Fasseeh, Ahmad ; Molnár, Anett ; Bitter, I. ; Horváth, Margit ; Kóczián, Kristóf ; Götze, Árpád ; Nagy, Balázs. / A systematic review of health economic models and utility estimation methods in schizophrenia. In: Expert Review of Pharmacoeconomics and Outcomes Research. 2018 ; Vol. 18, No. 3. pp. 267-275.
@article{f1c21a929ebd4e3f9ffaf0b40ef80b72,
title = "A systematic review of health economic models and utility estimation methods in schizophrenia",
abstract = "Introduction: There is a growing need for economic evaluations describing the disease course, as well as the costs and clinical outcomes related to the treatment of schizophrenia. Areas covered: A systematic review on studies describing health economic models in schizophrenia and a targeted literature review on utility mapping algorithms in schizophrenia were carried out. Models found in the review were collated and assessed in detail according to their type and various other attributes. Fifty-nine studies were included in the review. Modeling techniques varied from simple decision trees to complex simulation models. The models used various clinical endpoints as value drivers, 47{\%} of the models used quality-adjusted life years, and eight percent used disability-adjusted life years to measure benefits, while others applied various clinical outcomes. Most models considered patients switching between therapies, and therapeutic adherence, compliance or persistence. The targeted literature review identified four main approaches to map PANSS scores to utility values. Expert commentary: Health economic models developed for schizophrenia showed great variability, with simulation models becoming more frequently used in the last decade. Using PANSS scores as the basis of utility estimations is justifiable.",
keywords = "health economic models, Health economics, psychiatry, schizophrenia, systematic reviews",
author = "Bertalan N{\'e}meth and Ahmad Fasseeh and Anett Moln{\'a}r and I. Bitter and Margit Horv{\'a}th and Krist{\'o}f K{\'o}czi{\'a}n and {\'A}rp{\'a}d G{\"o}tze and Bal{\'a}zs Nagy",
year = "2018",
month = "5",
day = "4",
doi = "10.1080/14737167.2018.1430571",
language = "English",
volume = "18",
pages = "267--275",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - A systematic review of health economic models and utility estimation methods in schizophrenia

AU - Németh, Bertalan

AU - Fasseeh, Ahmad

AU - Molnár, Anett

AU - Bitter, I.

AU - Horváth, Margit

AU - Kóczián, Kristóf

AU - Götze, Árpád

AU - Nagy, Balázs

PY - 2018/5/4

Y1 - 2018/5/4

N2 - Introduction: There is a growing need for economic evaluations describing the disease course, as well as the costs and clinical outcomes related to the treatment of schizophrenia. Areas covered: A systematic review on studies describing health economic models in schizophrenia and a targeted literature review on utility mapping algorithms in schizophrenia were carried out. Models found in the review were collated and assessed in detail according to their type and various other attributes. Fifty-nine studies were included in the review. Modeling techniques varied from simple decision trees to complex simulation models. The models used various clinical endpoints as value drivers, 47% of the models used quality-adjusted life years, and eight percent used disability-adjusted life years to measure benefits, while others applied various clinical outcomes. Most models considered patients switching between therapies, and therapeutic adherence, compliance or persistence. The targeted literature review identified four main approaches to map PANSS scores to utility values. Expert commentary: Health economic models developed for schizophrenia showed great variability, with simulation models becoming more frequently used in the last decade. Using PANSS scores as the basis of utility estimations is justifiable.

AB - Introduction: There is a growing need for economic evaluations describing the disease course, as well as the costs and clinical outcomes related to the treatment of schizophrenia. Areas covered: A systematic review on studies describing health economic models in schizophrenia and a targeted literature review on utility mapping algorithms in schizophrenia were carried out. Models found in the review were collated and assessed in detail according to their type and various other attributes. Fifty-nine studies were included in the review. Modeling techniques varied from simple decision trees to complex simulation models. The models used various clinical endpoints as value drivers, 47% of the models used quality-adjusted life years, and eight percent used disability-adjusted life years to measure benefits, while others applied various clinical outcomes. Most models considered patients switching between therapies, and therapeutic adherence, compliance or persistence. The targeted literature review identified four main approaches to map PANSS scores to utility values. Expert commentary: Health economic models developed for schizophrenia showed great variability, with simulation models becoming more frequently used in the last decade. Using PANSS scores as the basis of utility estimations is justifiable.

KW - health economic models

KW - Health economics

KW - psychiatry

KW - schizophrenia

KW - systematic reviews

UR - http://www.scopus.com/inward/record.url?scp=85048494010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048494010&partnerID=8YFLogxK

U2 - 10.1080/14737167.2018.1430571

DO - 10.1080/14737167.2018.1430571

M3 - Review article

VL - 18

SP - 267

EP - 275

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 3

ER -